Preferred Label : Osilodrostat;

NCIt synonyms : (R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile;

NCIt definition : An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), with potential anti-adrenal activity and ability to treat Cushing disease (CD). Upon administration, osilodrostat binds to and inhibits the activity of CYP11B1, the enzyme that catalyzes the final step of cortisol synthesis from the precursor 11-deoxycortisol, and CYP11B2, the enzyme that catalyzes aldosterone synthesis from corticosterone and 11-deoxycorticosterone in the adrenal gland. The inhibition of CYP11B1 prevents the production of excess cortisol, thereby decreasing and normalizing the levels of cortisol. CD is most often caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.;

UNII : 5YL4IQ1078;

InChIKey : USUZGMWDZDXMDG-CYBMUJFWSA-N;

CAS number : 928134-65-0;

Molecule name : LCI-699; LCI 699;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.has-sante.fr/jcms/p_3265513/fr/isturisa-osilodrostat
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Osilodrostat
Osilodrostat
osilodrostat
administration, oral
adult
cushing syndrome
Endogenous Cushing Syndrome
evaluation of the transparency committee
imidazoles
pyridines

---
Nous contacter.
29/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.